SALT LAKE CITY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the presentation of blinded interim results from the Phase 2 RESCUE-ALS clinical trial investigating the effects of its lead clinical candidate, CNM-Au8, for the treatment of amyotrophic lateral sclerosis (ALS). CNM-Au8 is an aqueous suspension of clean-surfaced, faceted gold nanocrystals with catalytic activity that has been shown to enhance the metabolic energetic capacity of motor neurons while simultaneouslyreducing oxidative stress.
As of the data cutoff (October 27, 2020), the trial was fully enrolled with a preliminary blinded assessment of the studys primary endpoint, the motor neuron number index-4 [MUNIX(4)] score, showing that more than 40% of enrolled patients with completed week 12 data experienced improvements in motor neuron function assessed by MUNIX. When compared to baseline values, the average MUNIX(4) score of the overall trial population (including both active CNM-Au8 and placebo) experienced an absolute increase in mean MUNIX(4) values. This increase exceeded the expectations of the statistical modeling on which the study was based, which predicted a linear decline in average MUNIX(4) score from study onset (Neuwirth et al. JNNP 2015). These data, while blinded, suggest that CNM-Au8 may have neuro-reparative potential in ALS patients. Clene expects to report the complete, unblinded results from the RESCUE-ALS study in 2H 2021.
Although blinded to treatment assignment, these data are encouraging. We believe Clenes breakthrough approach with the application of physics to biology via direct electron interactions within cellular systems at the nano-scale may hold the potential to revolutionize the treatment of neurodegenerative diseases such as ALS and other motor neuron diseases, said Robert Glanzman, MD, FAAN, Chief Medical Officer of Clene.
Rob Etherington, President and CEO of Clene added, This blinded interim analysis suggests that CNM-Au8 is working mechanistically to address a foundational challenge common to many neurodegenerative diseases, namely that stressed or failing neurons need additional energy for their survival, repair, and improved function. Emerging MUNIX data potentially indicate preservation of motor units, which is promising. We eagerly anticipate final results and are encouraged that these blinded interim results may provide hope for ALS patients and their families as they search for new therapies to treat this devastating disease.
The presentation (CLT-23) titled, RESCUE-ALS Trial, A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in Amyotrophic Lateral Sclerosis Patients: Design and Interim Blinded Results, is available as a live e-Poster on December 10th at 12:10 12:50 pm EST at the Virtual 31st International Symposium on ALS/MND, held online (https://symposium.mndassociation.org/virtual-2020/).
About RESCUE-ALSRESCUE-ALS is a Phase 2 multi-center, randomized, double-blind, parallel group, placebo-controlled study examining the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in participants who are newly symptomatic with ALS (within 24-months of screening or 12-months from diagnosis). Enrolled subjects will be randomized 1:1 to receive either active treatment with CNM-Au8 (30 mg) or placebo in addition to their current standard of care. Participants will receive their randomized treatment over 36 consecutive weeks during the treatment period. The objective of this study is to assess the impact of improving neuronal bioenergetics, reducing reactive oxygen species and promoting protein homeostasis with CNM-Au8 to slow disease progression in patients with ALS. In the trial, efficacy is assessed as the average change in motor neuron unit number index (MUNIX) estimated by electromyography for the abductor digiti minimi (ADM), abductor pollicis brevis (APB), biceps brachii (BB), and tibialis anterior (TA) (muscles of the hand, arm, and leg). The trial was fully enrolled with 44 participants as of the reported 27-October-2020 data cut. Baseline characteristics include [mean (SD)], MUNIX(4) score: 93.7 (45.8); FVC % predicted: 80.8 (16.3); ALSFRS-R: 38.6 (6.1); ALSSQOL-20: 3.3 (1.3), mean time from diagnosis: 4.7 (4.6) months; riluzole background treatment, 92%.
About CNM-Au8CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted gold nanocrystals that act catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of pure gold nanoparticles, composed of clean-surfaced, faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteers and has shown both remyelination and neuroprotective effects in multiple preclinical (animal) models. Preclinical data, both published in peer-reviewed journals and presented at scientific congresses, demonstrate that treatment of neuronal cultures with CNM-Au8 improves survival of neurons, protects neurite networks, decreases intracellular levels of reactive oxygen species and improves mitochondrial capacity in response to cellular stresses induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 improved functional behaviors in rodent models of ALS, multiple sclerosis, and Parkinsons disease versus vehicle (placebo). CNM-Au8 is currently being tested in a Phase 2 clinical study for the treatment of chronic optic neuropathy in patients with MS in addition to Phase 2 and Phase 3 clinical studies for disease progression in patients with ALS.
About ALSALS is a universally fatal neurodegenerative disorder that results in loss of motor neurons in the cerebral cortex, brain stem, and spinal cord. ALS, also known as Lou Gehrig's disease, leads to the death of the neurons controlling voluntary muscles resulting in weakness, muscle atrophy, and progressive paralysis. ALS affects more than 15,000 patients in the United States and is the most prevalent adult-onset progressive motor neuron disease.
About CleneClene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit http://www.clene.com.
Forward-Looking StatementsThis press release contains, and certain oral statements made by representatives of Tottenham, Clene, and their respective affiliates, from time to time may contain, "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Tottenham's and Clene's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Tottenham's and Clene's expectations with respect to future performance and anticipated financial impacts of the business combination, the satisfaction of the closing conditions to the business combination and the timing of the completion of the business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Tottenham or Clene and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed business combination; (2) the outcome of any legal proceedings that may be instituted against Tottenham or Clene following the announcement of the Merger Agreement and the transactions contemplated therein; (3) the inability to complete the business combination, including due to failure to obtain approval of the shareholders of Tottenham or other conditions to closing in the Merger Agreement; (4) delays in obtaining or the inability to obtain necessary regulatory approvals (including approval from regulators, as applicable) required to complete the transactions contemplated by the Merger Agreement; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement or could otherwise cause the transaction to fail to close; (6) the inability to obtain or maintain the listing of the post-acquisition company's ordinary shares on NASDAQ following the business combination; (7) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; (8) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the business combination; (10) changes in applicable laws or regulations; (11) the possibility that Clene or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (12) other risks and uncertainties to be identified in the Form S-4 filed by Chelsea Worldwide (when available) relating to the business combination, including those under "Risk Factors" therein, and in other filings with the Securities and Exchange Commission (SEC) made by Tottenham and Clene. Tottenham and Clene caution that the foregoing list of factors is neither exclusive nor exhaustive. Tottenham and Clene caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Tottenham or Clene undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Media ContactAndrew MielachLifeSci Communications(646) 876-5868amielach@lifescicomms.com
Investor ContactBruce MackleLifeSci Advisors, LLC(929) 469-3859bmackle@lifesciadvisors.com
Continue reading here:
- Is there an alternative to radiation - November 8th, 2009 [November 8th, 2009]
- Taiwan exploring how nanotech affects health - November 8th, 2009 [November 8th, 2009]
- A new way of treating cancer on the way? - November 8th, 2009 [November 8th, 2009]
- Lasers can destroy cancer cells - November 8th, 2009 [November 8th, 2009]
- Fluorescent molecules can be biomarkers - November 8th, 2009 [November 8th, 2009]
- Quick blood tests by using a nanodevice - November 8th, 2009 [November 8th, 2009]
- Where will medicine be 20 years from now - November 8th, 2009 [November 8th, 2009]
- History of nanotechnology - November 8th, 2009 [November 8th, 2009]
- Nanotech and Cancer - November 8th, 2009 [November 8th, 2009]
- Nanotechnology in medicine - November 8th, 2009 [November 8th, 2009]
- How does cancer start - January 25th, 2010 [January 25th, 2010]
- Lung cancer symptoms - January 26th, 2010 [January 26th, 2010]
- Signs of breast cancer - January 27th, 2010 [January 27th, 2010]
- Famous people with cancer - January 29th, 2010 [January 29th, 2010]
- Metastatic renal cancer - January 30th, 2010 [January 30th, 2010]
- What causes skin cancer - January 31st, 2010 [January 31st, 2010]
- How many people die from cancer each year - February 1st, 2010 [February 1st, 2010]
- How much money is spent on cancer research - February 2nd, 2010 [February 2nd, 2010]
- Colon cancer warning signs - February 4th, 2010 [February 4th, 2010]
- Prostate cancer symptoms - February 4th, 2010 [February 4th, 2010]
- Nano-devices that cross blood-brain barrier open door to treatment of cerebral palsy - April 25th, 2012 [April 25th, 2012]
- Nano-devices that cross blood-brain barrier open door to treatment of cerebral palsy, other neurologic disorders - April 25th, 2012 [April 25th, 2012]
- Nanomaterial properties in complement activation: lessons from nanomedicine - Video - May 4th, 2012 [May 4th, 2012]
- OMICS Group :: International Conference and Exhibition on Nanotechnology - May 4th, 2012 [May 4th, 2012]
- Use of Nanotechnology in Medicine [FOX 11-27-2011] - Video - May 4th, 2012 [May 4th, 2012]
- Cancer Nanomedicine - Detection - Video - May 4th, 2012 [May 4th, 2012]
- Cancer Nanomedicine - Video - May 4th, 2012 [May 4th, 2012]
- HBIO Reports First Quarter 2012 Revenue Growth of 8% Over First Quarter 2011 - May 5th, 2012 [May 5th, 2012]
- Nano science, focus of Education Ministry - May 7th, 2012 [May 7th, 2012]
- Drug-resistant Bacteria - Designing Nanoparticles For High Antibiotic Doses - May 7th, 2012 [May 7th, 2012]
- Research and Markets: Global Market for Nano Silver - May 10th, 2012 [May 10th, 2012]
- Cracking study makes nanotech breakthrough - May 10th, 2012 [May 10th, 2012]
- Nanoparticles may pose environmental threat - May 16th, 2012 [May 16th, 2012]
- Global Nanobiotechnology Industry - May 17th, 2012 [May 17th, 2012]
- 'Inability to give back Singur land my biggest regret' - May 20th, 2012 [May 20th, 2012]
- 'KOREA PACK 2012' for Packing process industry to be held at KINTEX - May 23rd, 2012 [May 23rd, 2012]
- New ISO Technical Report Guides Characterization of Nanomaterials in Toxicology - May 29th, 2012 [May 29th, 2012]
- DNA strands create tiniest Smileys - May 30th, 2012 [May 30th, 2012]
- Health and fitness agenda: Evolution Asia Yoga Conference - June 2nd, 2012 [June 2nd, 2012]
- UC Davis work in humanities receives $150,000 in UC-wide grants - June 2nd, 2012 [June 2nd, 2012]
- Computer-designed proteins 'may help fight variety of flu viruses' - June 3rd, 2012 [June 3rd, 2012]
- 'Nano technology' [program can pay off big for IRSC students - June 3rd, 2012 [June 3rd, 2012]
- Computer-designed proteins programmed to disarm variety of flu viruses - June 3rd, 2012 [June 3rd, 2012]
- Jugaad innovators don't plan - they improvise - June 6th, 2012 [June 6th, 2012]
- Health and fitness agenda: World Blood Donor Day - June 9th, 2012 [June 9th, 2012]
- OMICS Group :: Journal of Nanomedicine - June 9th, 2012 [June 9th, 2012]
- Researchers develop a 'time bomb' to fight cardiovascular disease - June 10th, 2012 [June 10th, 2012]
- Nanotechnologists develop a 'time bomb' to fight cardiovascular disease - June 10th, 2012 [June 10th, 2012]
- 'Time bomb' to fight cardiovascular disease developed - June 11th, 2012 [June 11th, 2012]
- Asia's First Graphene Nano-Tech Facility Opens In Singapore - June 13th, 2012 [June 13th, 2012]
- How worms are pioneering remote control medicine - June 13th, 2012 [June 13th, 2012]
- Golden Helix Establishes Direct Presence in Japan - June 13th, 2012 [June 13th, 2012]
- STDs Blocked by Nano Gel, Study Suggests - June 15th, 2012 [June 15th, 2012]
- Real Products, Different Results - June 15th, 2012 [June 15th, 2012]
- The Puridone Program - A Breakthrough for Painkiller Addiction - June 15th, 2012 [June 15th, 2012]
- Six startup medical device firms compete in Memphis for fame and fortune - June 19th, 2012 [June 19th, 2012]
- International Nanomedicine Conference bound for Sydney: July 2-4, 2012 - June 19th, 2012 [June 19th, 2012]
- Taming light with graphene - June 21st, 2012 [June 21st, 2012]
- Today on New Scientist: 25 June 2012 - June 26th, 2012 [June 26th, 2012]
- A step towards the future - July 1st, 2012 [July 1st, 2012]
- Genia Technologies Collaborates with Professors Jingyue Ju at Columbia and George Church at Harvard to Develop a ... - October 4th, 2012 [October 4th, 2012]
- Scientists Invited To Submit Proposals For Biological Research In Space - October 4th, 2012 [October 4th, 2012]
- Research and Markets: Micro-Nano Technology XIII from the 13th Annual Conference of Chinese Society of Micro-Nano ... - October 6th, 2012 [October 6th, 2012]
- $80M research facility to open at UMass Lowell - October 6th, 2012 [October 6th, 2012]
- Nano-revolution in drugs delivery - October 8th, 2012 [October 8th, 2012]
- SENAI/SESI of Sao Paulo Selects NanoProfessor as Foundation for "Nanomundo" Nanotechnology Education Initiative - October 8th, 2012 [October 8th, 2012]
- Delivering an integral approach to emotional and mental health - October 9th, 2012 [October 9th, 2012]
- NanoGuardian's On-Dose NanoEncryption Brand Protection Technology to Be Presented at AAPS Annual Meeting - October 11th, 2012 [October 11th, 2012]
- Il Nano Mondo del professor Ennio Tasciotti - Video - October 30th, 2012 [October 30th, 2012]
- Deakin University - Practical Science - Nano medicine - Video - October 30th, 2012 [October 30th, 2012]
- 2012 Deakin University 3 Minute Thesis Finalist - Jarrad Altimari - Video - October 30th, 2012 [October 30th, 2012]
- Nano Medicine from "Development of Nanotechnology in Hong Kong" - Video - October 30th, 2012 [October 30th, 2012]
- NANO Medicine 1 3 xvid - Video - October 30th, 2012 [October 30th, 2012]
- Nanolääke // Nano medicine - Video - October 30th, 2012 [October 30th, 2012]
- NANO Medicine (1-3) - Video - October 30th, 2012 [October 30th, 2012]
- Jefferson County, Colorado's Bioscience Industry - Video - October 30th, 2012 [October 30th, 2012]
- NanoMission - Nanomedicine NanoBot - Video - October 30th, 2012 [October 30th, 2012]
- Study aims to unlock mysteries of autism - November 20th, 2012 [November 20th, 2012]
- Catherine Griwkowsky - November 22nd, 2012 [November 22nd, 2012]
- Kulkarni to be feted at Bangalore Nano 2012 - November 26th, 2012 [November 26th, 2012]